Journal of Pediatric Health Care
Volume 24, Issue 3 , Pages 184-188 , May 2010

Treatment of Intravenous Infiltration in a Neonate

  • Laura L. Kuensting, MSN(R), RN, CPNP, CPEN

      Affiliations

    • Corresponding Author InformationCorrespondence: Laura L. Kuensting, MSN(R), RN, CPNP, CPEN, St. John's Mercy Children's Hospital, 621 S New Ballas Rd, Suite 6006B, St. Louis, MO 63141

References 

  1. Allen CH, Etzwiler LS, Miller MK, Maher G, Mace S, Hostetler MA, et al Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration. Pediatrics. 2009;124:e859–e868
  2. Baxter Healthcare Corporation . Hylenex (hyaluronidase human injection). [product information] Deerfield, IL: Author; 2009;
  3. Bertelli G, Dini D, Forno GB, Gozza A, Silvestro S, Venturini M, et al Hyaluronidase as an antidote to extravasation of Vinca alkaloids: Clinical results. Journal of Cancer Research and Clinical Oncology. 1994;120:505–506
  4. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, et al A recombinant human enzyme for enhanced interstitial transport of therapeutics. Journal of Controlled Release. 2006;114:230–241
  5. Boyle DM, Engelking C. Vesicant extravasation: Myths and realities. Oncology Nursing Forum. 1995;22:57–67
  6. Cochran ST, Bomyea K, Kahn M. Treatment of iodinated contrast material extravasation with hyaluronidase. Academic Radiology. 2002;9(Suppl. 2):S544–S546
  7. Dorr RT, Alberts DS. Vinca alkaloid skin toxicity: Antidote and drug disposition studies in the mouse. Journal of the National Cancer Institute. 1985;74:113–120
  8. Dorr RT, Snead K, Liddil JD. Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer. 1996;78:152–156
  9. Ebo DG, Goossens S, Opsomer F, Bridts CH, Stevens WJ. Flow-assisted diagnosis of anaphylaxis to hyaluronidase. Allergy. 2005;60:1333–1334
  10. Fullilove S, Fixsen J. Major limb deformities as complications of vascular access in neonates. Paediatric Anaesthesia. 1997;7:247–250
  11. Guidance for industry: Pharmaceutical components at risk for melamine contamination. (2009). Retrieved from Food and Drug Administration website: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Gdances/default.htm
  12. Heckler FR. Current thoughts on extravasation injuries. Clinics in Plastic Surgery. 1989;16:557–563
  13. Heckler FR, McCraw JB. Calcium-related cutaneous necrosis. Surgical Forum. 1976;27:553–555
  14. Humphrey GB, Boon CMJ, van Linden van den Heuvell GFEC, van de Wiel HM. The occurrence of high levels of acute behavioral distress in children and adolescents undergoing routine venipunctures. Pediatrics. 1992;90:87–91
  15. Intravenous Nursing Society . Infiltration/extravasation. Journal of Intravenous Nursing. 1998;21:S36–S37
  16. Kumar MM, Sprung J. The use of hyaluronidase to treat mannitol extravasation. Anesthesia & Analgesia. 2003;97:1199–1200
  17. Laurie SW, Wilson KL, Kernahan DA, Bauer BS, Vistnes LM. Intravenous extravasation injuries: The effectiveness of hyaluronidase in their treatment. Annals of Plastic Surgery. 1984;13:191–194
  18. Liu SW, Zane R. Peripheral intravenous access. In:  Roberts JR,  Hedges JR editor. Clinical procedures in emergency medicine. 4th ed. Philadelphia, PA: Saunders; 2004;p. 401–412
  19. Loth TS. Minimal surgical debridement for the treatment of chemotherapeutic agent-induced skin extravasations. Cancer Treatment Report. 1986;70:401–404
  20. Lund CH, Kuller JM. Integumentary system. In:  Kenner C,  Lott JW editor. Comprehensive neonatal care—an Interdisciplinary approach. 4th ed. Philadelphia, PA: Saunders; 2007;p. 65–91
  21. Pirrello RD, Ting Chen C, Thomas SH. Initial experiences with subcutaneous recombinant human hyaluronidase. Journal of Palliative Medicine. 2007;10:861–864
  22. Raszka WV, Kueser TK, Smith FR, Bass JW. The use of hyaluronidase in the treatment of intravenous extravasation injuries. Journal of Perinatology. 1990;10:146–149
  23. Schulmeister L. Managing vesicant extravasations. Oncologist. 2008;13:284–288
  24. Schummer W, Schummer C, Bayer O, Muller A, Bredle D, Karzai W. Extravasation injury in the perioperative setting. Anesthesia & Analgesia. 2005;100:722–727
  25. Schwartzman J. Hyaluronidase; a review of its therapeutic use in pediatrics. Journal of Pediatrics. 1951;39:491–502
  26. Szépfalusi Z, Nentwich I, Dobner M, Pillwein K, Urbanek R. IgE mediated allergic reaction to hyaluronidase in paediatric oncological patients. European Journal of Pediatrics. 1997;156:199–203
  27. Thigpen JL. Peripheral intravenous extravasation: Nursing procedure for initial treatment. Neonatal Network. 2007;26:379–384
  28. Thomas JR, Yocum RC, Haller MF, von Gunten CF. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: The INFUSE-LR study. Journal of Palliative Medicine. 2007;10:1312–1320
  29. Yocum RC, Kennard D, Heiner LS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: A double-blind, placebo-controlled clinical trial. Journal of Infusion Nursing. 2007;30:293–299
  30. Zenk KE, Dungy CI, Greene GR. Nafcillin extravasation injury. Use of hyaluronidase as an antidote. American Journal of Diseases of Children. 1981;135:1113–1114

 Laura Kuensting has served as a consultant on a nurse advisory board, as a consultant, and has participated in the Speakers' Bureau for Baxter Healthcare Corporation, Inc., Deerfiend, IL. Editorial assistance in the preparation of this manuscript was funded by Baxter Healthcare Corporation.

PII: S0891-5245(10)00026-X

doi: 10.1016/j.pedhc.2010.02.001

Journal of Pediatric Health Care
Volume 24, Issue 3 , Pages 184-188 , May 2010

Article Tools